Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
6.54
+0.27 (4.31%)
At close: Mar 2, 2026, 4:00 PM EST
6.38
-0.16 (-2.45%)
Pre-market: Mar 3, 2026, 5:19 AM EST
Company Description
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials.
It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Shane Schaffer |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas 66205 United States | |
| Phone | 913 942 2300 |
| Website | cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W3034 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer and Director |
| Jennifer L. Callahan CPA | SVice President, Chief Financial Officer and Secretary |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President and Chief Science Officer |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President and Chief Medical Officer |
| Thomas Dalton | Vice President of Investor and Public Relations |
| Nilay Patel J.D. | Chief Legal Officer |
| Downey Bryan Wade | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 2, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 18, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SCHEDULE 13D | Filing |
| Feb 6, 2026 | 8-K | Current Report |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 15, 2026 | 8-K | Current Report |
| Jan 12, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 12, 2026 | 424B5 | Filing |
| Jan 2, 2026 | 8-K | Current Report |